Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.42 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 7/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.38 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.36 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.36 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.35 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3727493 | 0.91 | TYMP (0.42) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL18787574 | 0.91 | TYMP (0.42) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL10049741 | 0.90 | TYMP (0.41) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL10049738 | 0.90 | TYMP (0.38) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL10049842 | 0.89 | TYMP (0.37) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL10050040 | 0.88 | TYMP (0.36) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL1327824 | 0.87 | TYMP (0.40) | TYMPADORA2BADORA1ADORA3PRKAG1 | |
| SCHEMBL22787252 | 0.85 | TYMP (0.42) | TYMPADORA2BADORA1ADORA3 | |
| SCHEMBL10049845 | 0.85 | TYMP (0.38) | TYMPADORA2BADORA1ADORA3DOT1L | |
| SCHEMBL10049839 | 0.85 | TYMP (0.37) | TYMPADORA2BADORA1ADORA3PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | SOLSTICE BIOLOGICS LTD (IE) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200392498-A1 | POLYNUCLEOTIDE CONSTRUCTS HAVING BIOREVERSIBLE AND NON-BIOREVERSIBLE GROUPS | HNRNPC, RNASE1, NSUN3 | TYMP 190/4885ADORA2B 4023/4885ADORA1 4609/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.